The role of pharmacogenomics in the discontinuation of psychotropic medication: a scoping review protocol

Natalia Stollarova; Cristín Ryan; Greg Sheaf; Dolores Keating; Brian O’Donoghue; Cathal Cadogan

doi:10.12688/hrbopenres.14314.1

Home Browse The role of pharmacogenomics in the discontinuation of psychotropic...

ALL Metrics

-

Views

3

Downloads

Get PDF

Get XML

Export

▬

✚

Study Protocol

The role of pharmacogenomics in the discontinuation of psychotropic medication: a scoping review protocol

[version 1; peer review: awaiting peer review]

Natalia Stollarova^1,2, Cristín Ryan¹, Greg Sheaf³, Dolores Keating⁴, Brian O’Donoghue⁵, Cathal Cadogan ¹

Natalia Stollarova^1,2, Cristín Ryan¹, [...] Greg Sheaf³, Dolores Keating⁴, Brian O’Donoghue⁵, Cathal Cadogan ¹

PUBLISHED 05 Jan 2026

Author details Author details

¹ School of Pharmacy and Pharmaceutical Sciences, Trinity College Dublin, Dublin, Ireland
² Department of Pharmacology and Toxicology, Faculty of Pharmacy, Comenius University Bratislava, Bratislava, Slovakia
³ The Library of Trinity College, Trinity College Dublin, Dublin, Ireland
⁴ Pharmacy Department, Saint John of God University Hospital, Dublin, Stillorgan, Ireland
⁵ Department of Psychiatry, School of Medicine, University College Dublin, Dublin, Ireland

Natalia Stollarova
Roles: Conceptualization, Funding Acquisition, Investigation, Methodology, Project Administration, Writing – Original Draft Preparation

Cristín Ryan
Roles: Writing – Review & Editing

Greg Sheaf
Roles: Methodology, Writing – Review & Editing

Dolores Keating
Roles: Writing – Review & Editing

Brian O’Donoghue
Roles: Writing – Review & Editing

Cathal Cadogan
Roles: Conceptualization, Funding Acquisition, Investigation, Methodology, Project Administration, Writing – Original Draft Preparation

OPEN PEER REVIEW

REVIEWER STATUS AWAITING PEER REVIEW

Abstract

Introduction

Discontinuation of psychotropic medication is associated with considerable clinical challenges, including withdrawal symptoms and relapse. Pharmacogenomic testing is increasingly used in clinical practice to optimise pharmacotherapy by guiding drug selection and dosing, however, its role in informing medication discontinuation and tapering strategies remains underexplored. Understanding the influence of genetic variability on withdrawal symptoms could support safer, individualised discontinuation practices.

Objective

This scoping review aims to map the available evidence on the role of pharmacogenomics on the discontinuation of psychotropic medications.

Methods

The review will be conducted in accordance with the Joanna Briggs Institute (JBI) methodology for scoping reviews and reported using the PRISMA-ScR checklist. Comprehensive searches will be performed in MEDLINE, EMBASE, CINAHL, Web of Science, and PsycINFO. Studies exploring gene polymorphisms relevant to the discontinuation of psychotropic medications (antidepressants, antipsychotics, mood stabilisers, anxiolytics, hypnotics, stimulants, and opioids) will be considered. Following screening, data will be extracted, and a narrative synthesis will be undertaken to map characteristics of included studies, genes studied, medication classes involved, reported outcomes, and knowledge gaps.

Conclusion

This review will provide an overview of existing evidence and identify gaps regarding the role of pharmacogenomics in psychotropic medication discontinuation. The findings will help to inform future research on the integration of pharmacogenomics into individualised tapering strategies.

Keywords

Pharmacogenomics, Psychotropic medications, Discontinuation, Withdrawal, Tapering, Precision medicine, Scoping review

Corresponding author: Cathal Cadogan

Competing interests: No competing interests were disclosed.

Grant information: Health Research Board Ireland [ILP-HSR-2022-006]. This work was also supported by the Erasmus+ Programme of the European Union.

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright: © 2026 Stollarova N et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite: Stollarova N, Ryan C, Sheaf G et al. The role of pharmacogenomics in the discontinuation of psychotropic medication: a scoping review protocol [version 1; peer review: awaiting peer review]. HRB Open Res 2026, 9:4 (https://doi.org/10.12688/hrbopenres.14314.1) First published: 05 Jan 2026, 9:4 (https://doi.org/10.12688/hrbopenres.14314.1) Latest published: 05 Jan 2026, 9:4 (https://doi.org/10.12688/hrbopenres.14314.1)

Introduction

Discontinuation of psychotropic medications presents a considerable and increasingly recognised clinical challenge^1,2. Psychotropic medications typically include drugs that have effects on the central nervous system, with an influence on thinking, mood, consciousness, behaviour, or other mental processes. The term psychotropic medications generally encompasses a broad group of drugs, most commonly antidepressants, antipsychotics, mood stabilisers, anxiolytics, hypnotics, stimulants, and opioids³. For patients treated with these medications, the process of dose reduction, cessation, or replacement can trigger withdrawal symptoms and/or, relapse of the underlying condition^1,2,4,5. Withdrawal symptoms can range from mild and short-lived to severe and persistent⁶. Initial withdrawal symptoms may include dizziness, headache, nausea, vomiting, irritability, anxiety, insomnia, vivid dreams, sensory disturbances, tremors, and in some cases, seizures. Protracted withdrawal symptoms may manifest as memory loss and concentration difficulties, hyperalgesia, and others^6,7. However, considerable difficulties still exist in distinguishing symptoms of the original condition for which the medication was first prescribed and those induced by the discontinuation of the medication^7,8. Furthermore, several factors influence the onset and course of withdrawal symptoms, including patient related factors (e.g. age and gender^9,10, psychological factors^11,12, and genetic predisposition^13,14), and medication-related factors (e.g. type of medication^7,15–17, dosage and duration of medication use^9,11,17, and drug half-life^7,18). Recognising these factors is crucial for prevention, early detection, and management of withdrawal symptoms.

A recent comprehensive systematic review on antidepressant treatment found that approximately one in three patients discontinuing these medications experience withdrawal symptoms, however, the frequency and intensity of these symptoms differ among antidepressant classes¹⁹. Symptoms commonly emerge within a few days of dose reduction or cessation and are often transient, though in some cases they persist for several weeks or months¹⁸. The onset and severity of discontinuation symptoms are strongly influenced by pharmacokinetic factors such as elimination half-life and metabolic rate. Antidepressants with short half-lives, such as paroxetine and venlafaxine, are associated with more frequent and severe withdrawal reactions compared with longer-acting drugs like fluoxetine¹⁸. Differences in metabolism further contribute to variability, as several drugs depend on cytochrome P450 (CYP450) enzymes for elimination. Consequently, patients who are rapid metabolisers may experience faster drug clearance and more abrupt plasma concentration changes, leading to higher risk of withdrawal symptoms. For example, paroxetine, which is a substrate and strong inhibitor of CYP2D6 with a short half-life, may produce more severe discontinuation effects in rapid metabolisers than in normal or poor metabolisers²⁰.

To minimise withdrawal symptoms in patients taking psychotropic medications, clinical practice guidelines emphasise gradual dose reduction and patient education on the risks of abrupt cessation. For example, most guidelines recommend reducing antidepressant doses progressively over a period of at least four weeks^18,21,22. Similar strategies apply to the discontinuation of other psychotropic agents including antipsychotics²³, benzodiazepine and benzodiazepine receptor agonists²⁴, mood stabilisers²⁵, and opioids²⁶. Overall, gradual tapering of psychotropic medications is consistently associated with a lower incidence and severity of withdrawal symptoms compared with abrupt or rapid discontinuation, yet standardised uniform tapering protocols across drug classes are still lacking²⁷.

Pharmacogenomics examines the influence of gene polymorphisms on individual responses to medications including the risk of adverse effects, toxicity, or therapeutic failure²⁸. Pharmacogenomic testing has already been implemented in clinical practice primarily using two types of approaches: pre-emptive and reactive²⁹. The pre-emptive approach seeks to optimise drug therapy by testing patients for multiple pharmacogenetic variants before any specific pharmacotherapy is initiated, leading to more personalised genotype-guided prescription³⁰. Reactive pharmacogenomic testing is performed in response to a prescribing decision and typically involves single-gene analysis to guide an immediate therapeutic choice²⁸. However, because results are obtained after the medication is prescribed, this approach can delay treatment adjustments, pose safety risks, and is less efficient than pre-emptive testing^28,31. Although pre-emptive pharmacogenomic testing presents greater challenges for routine implementation, it is generally considered a more desirable strategy than reactive testing^31,32.

While pharmacogenomics has been extensively explored in relation to treatment efficacy and adverse drug reactions, its role in medication discontinuation and withdrawal symptoms remains insufficiently studied. Preliminary studies suggest that genetic variability may modulate susceptibility to withdrawal symptoms, implicating pharmacogenomic differences in interindividual variability during discontinuations^13,33. Integrating pharmacogenomic insights into deprescribing and tapering strategies could therefore enhance the precision, safety, and personalisation of withdrawal management.

Accordingly, this scoping review aims to synthesise the available evidence on the role of pharmacogenomics in the discontinuation of psychotropic medication.

Methods

Given that existing evidence on gene polymorphisms, tapering, and withdrawal outcomes is dispersed across diverse study designs and therapeutic contexts, a scoping review represents the most appropriate approach to systematically map and synthesise current knowledge. This methodology will allow for the inclusion of studies with diverse designs and outcomes, assessment of the available research, identification of key concepts, as well as knowledge gaps, thereby providing a foundation for future systematic reviews and evidence-based clinical recommendations.

The scoping review will be conducted in accordance with the Joanna Briggs Institute (JBI) methodology for scoping reviews and reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) methodology³⁴. The adapted items of the PRISMA-P checklist for scoping reviews have been used in reporting this protocol³⁵.

Scoping review question

The research question was developed in accordance with the Population Concept Context (PCC) framework³⁶:

What is the available evidence regarding the role of pharmacogenomics (concept) on patients treated with psychotropic medications (population) in the process of the medication discontinuation (context)?

Population

The eligible population for this review is patients treated with psychotropic medications (antidepressants, antipsychotics, mood stabilisers, anxiolytics, hypnotics, stimulants, and opioid medications). No age restrictions will apply.

Concept

This scoping review will consider any evidence examining the role of pharmacogenomics in drug metabolism, transport, and receptor response (e.g., CYP enzymes, GABA receptors, ABCB1, COMT, OPRM1, SLC6A4, HTR2A, BDNF, and UGT enzymes) in the course of medication discontinuation.

Context

The review will include literature focusing on the process of medication discontinuation, including factors such as the duration and rate of tapering, the occurrence of withdrawal symptoms, and adverse drug reactions (ADRs) during dose reduction. Studies reporting on the success rate of discontinuation, relapse rates, or the need for treatment re-initiation will also be considered within the scope of this review.

Defining and aligning the objectives and research question

This scoping review aims to map available evidence on the role of pharmacogenomics in the process of psychotropic medication discontinuation.

The objectives of this scoping review are to:

1. Map the scope and characteristics of existing literature describing pharmacogenomics associated with the process of discontinuing psychotropic medications, with specific attention to withdrawal symptoms, duration and rate of tapering, relapse rates, and discontinuation outcomes.
2. Summarise specific gene–drug or gene–drug class associations that have been investigated in relation to medication discontinuation and withdrawal symptoms.
3. Identify existing knowledge gaps and propose directions for future research on the role of pharmacogenomics in the discontinuation of psychotropic medication.

Eligibility criteria

The eligibility criteria were defined according to the PCC framework, which ensures that the inclusion of studies is comprehensive and aligned with the objectives of the review. All study designs and evidence types relevant to the research question will be considered to capture the full extent of available knowledge. The inclusion and exclusion criteria are summarised in Table 1.

Table 1. Eligibility criteria for literature inclusion in the scoping review.

Inclusion criteria	Exclusion criteria
Population Patients treated with psychotropic medication (antidepressants, antipsychotics, anxiolytics, hypnotics, mood stabilisers, stimulants, opioids).	Patients not taking psychotropic medication.
Concept The role of pharmacogenomics in drug metabolism, transport, and receptor response (e.g., CYP enzymes, GABA receptors, ABCB1, COMT, OPRM1, SLC6A4, HTR2A, BDNF, and UGT enzymes) in the course of medication discontinuation.	Genetic variants not related to psychotropic medications.
Context The process of medication discontinuation including the duration and rate of tapering, withdrawal symptoms, relapse rates, etc.	Literature focused on initiation or response to psychotropic medications (as opposed to discontinuation).
Type of studies Systematic reviews RCTs, non-RCT, and pilot RCTs Observational studies Case-control studies Cohort studies (prospective and retrospective) Cross-sectional studies Qualitative studies Case studies	Opinion pieces Conference abstracts Study protocols Grey literature (e.g., theses, dissertations)

RCT – Randomised Controlled Trial

Information sources

To carry out the search, a three-step process recommended by the JBI Manual for Evidence Synthesis³⁴ will be followed. An initial limited search of Web of Science was conducted to identify relevant articles, using keywords and MeSH terms derived from the PCC framework (Table 2). The preliminary search strategy, developed in collaboration with a specialist librarian, has been completed for Web of Science. The search strategy will be further adapted for the following databases:

Table 2. Relevant search terms following the Population Concept Context (PCC) framework with keywords for Web of Science.

	POPULATION	CONCEPT	CONTEXT
Web of Science	Psychotropic drugs Psychiatric medications Antidepressants Antipsychotics Anxiolytics Hypnotics Mood stabilisers Neuroleptics Benzodiazepines Z-drugs Stimulants Opioids	Pharmacogenomics Pharmacogenetics Pharmacogenetic testing Genetic testing Genotyping Gene polymorphism Gene variant Single nucleotide polymorphism SNP CYP enzymes GABA receptor ABCB1 COMT OPRM1 SLC6A4 HTR2A BDNF UGT enzymes Biomarker Metaboliser	Deprescribing Tapering Dose reduction Treatment cessation Drug discontinuation Medication discontinuation Drug withdrawal Withdrawal symptoms Rebound symptoms Abstinence syndrome

MEDLINE
CINAHL
EMBASE
PSYCINFO

The reference list of identified studies will be further reviewed for additional sources.

Search strategy

All studies obtained from the literature searches will be imported into Covidence®³⁷, an online review management tool, to support systematic organisation, and screening. All duplicates will be removed. Each identified title will first be screened against the predefined inclusion and exclusion criteria (Table 1), followed by assessment of abstracts and subsequently full-text articles. Two reviewers will perform the screening independently, and any discrepancies will be resolved through discussion with a third reviewer. Reasons for exclusion at the full-text stage will be documented. The search strategy for Web of Science is documented in Table 3.

Table 3. Search strategy for Web of Science.

Search terms relating to population (separated by Boolean operator ’OR’)	(agomelatine OR alfentanil OR alprazolam OR amisulpride OR amitriptyline OR antipsychotic* OR antidepressant* OR anxiolytic* OR aripiprazole OR atomoxetine OR benzodiazepine* OR brexpiprazole OR bromazepam OR buprenorphine OR bupropion OR buspirone OR carbamazepine OR cariprazine OR chlorpromazine OR citalopram OR clomipramine OR clonazepam OR clorazepate OR clozapine OR codeine OR desipramine OR desvenlafaxine OR diazepam OR doxepin OR duloxetine OR escitalopram OR fentanyl OR fluoxetine OR fluvoxamine OR flurazepam OR gabapentin OR haloperidol OR hypnotic* OR hydrocodone OR hydromorphone OR iloperidone OR imipramine OR lamotrigine OR levomethadone OR levomilnacipran OR lithium OR lorazepam OR lumateperone OR lurasidone OR methadone OR methylphenidate OR milnacipran OR midazolam OR mirtazapine OR "mood stabiliser" OR "mood stabilizer" OR morphine OR naltrexone OR neuroleptic* OR nitrazepam OR nortriptyline OR opioid* OR opiate* OR oxazepam OR oxcarbazepine OR oxycodone OR paliperidone OR paroxetine OR pimavanserin OR pregabalin OR quetiapine OR remifentanil OR risperidone OR "selective serotonin reuptake inhibitor" OR "serotonin norepinephrine reuptake inhibitor" OR SNRI* OR SSRI* OR sertraline OR stimulant* OR sufentanil OR sulpiride OR tapentadol OR temazepam OR "TCA" OR topiramate OR tramadol OR triazolam OR trifluoperazine OR trimipramine OR valproate OR venlafaxine OR vilazodone OR vortioxetine OR "z drug" OR ziprasidone OR zolpidem OR zopiclone OR ((psychiatric OR psychotropic) NEAR/2 (drug* OR medication* OR medicine* OR pharmaceutical* OR substance* OR therap*)))
Boolean operator	AND
Search terms relating to concept (separated by Boolean operator ’OR’)	("ABCB" OR allele OR "BDNF" OR biomarker OR "COMT" OR "CYP" OR "GABA receptor" OR genotyp OR "HTR2A" OR metaboliser OR metabolizer* OR "OPRM1" OR "PGx" OR pharmacogen* OR phenotype* OR "serotonin transporter" OR "single nucleotide polymorphism" OR "SLC6A4" OR "SNP" OR "UGT" OR (gene NEAR/2 (polymorphism* OR test* OR variant*)))
Boolean operator	AND
Search terms relating to context (separated by Boolean operator ’OR’)	(deprescrib* OR taper* OR ((abstinence OR discontinuation OR rebound OR withdrawal) NEAR/2 (symptom* OR syndrome)) OR ((dose OR drug* OR medication* OR medicine* OR pharmaceutical* OR substance* OR therap* OR treatment) NEAR/2 (cessation OR discontinu OR reduc* OR wean* OR withdraw*)))

The process of identification of studies will be illustrated using a PRISMA flow diagram adapted for scoping reviews – PRISMA-ScR flow diagram³⁸.

Data charting

Data extraction from the included studies will be conducted by two reviewers using a predefined data extraction form. To ensure consistency and accuracy, a random 20% subset of the studies will be independently extracted by a third reviewer, and the results will be compared. The preliminary types of information that will be extracted are:

Author(s)/Study citation
Year of publication
Origin/country of origin
Aims/purpose
Type of study
Research design and methodology (e.g. type of genotyping, tapering)
Population characteristics (type of pharmacotherapy)
Sample size
Investigated gene polymorphisms
Description of medication discontinuation process (including withdrawal symptoms, duration and rate of tapering, ADE, success rate, etc.)
Key findings related to scoping review questions

Any revisions of types of information during the extraction process will be documented and reported in the final scoping review.

Data relevant to the review objectives and research question will be extracted, including study characteristics (author, year, country, design), population details, type of pharmacotherapy, investigated gene polymorphisms, discontinuation process, and key findings.

Any discrepancies between reviewers during data extraction will be discussed and resolved through consensus, with input from additional reviewer from the research team if required.

Critical appraisal

Given that this scoping review is intended to provide a broad overview of the available literature, critical appraisal of the included studies is not recommended by the current JBI guidance³⁴.

Data analysis and synthesis

Key study characteristics and findings will be summarised in tabular form, with the table structure refined during the data extraction phase. A narrative synthesis will accompany the tables to provide an overview of the evidence concerning gene polymorphisms associated with the discontinuation of psychotropic medications, including the genes studied, medication classes, outcomes, and study designs. The analysis will focus on mapping and characterising the existing evidence rather than synthesising study results. Existing gaps in the literature and areas requiring further research will also be identified and highlighted.

Discussion

Pharmacogenomic testing is increasingly recognised as a tool to optimise pharmacotherapy by reducing adverse effects, toxicity, improving treatment efficacy²⁸, and supporting the personalisation of therapy. However, the potential role of gene polymorphisms in influencing withdrawal symptoms and the tapering process remains poorly understood and underexplored. This represents a significant gap, particularly for psychotropic medication, where discontinuation is frequently complicated by variable patient responses.

This scoping review will address this gap by systematically mapping existing evidence on the role of pharmacogenomic factors in the discontinuation of psychotropic medication. The review will chart the characteristics of included studies, study designs, the investigated genes, medication classes, and reported outcomes. The findings will provide an overview of the current state of evidence, identify areas where research is lacking, and potentially establish a foundation for understanding how pharmacogenomic variation may contribute to interindividual differences in discontinuation outcomes. Ultimately, this review may inform future research aimed at integrating pharmacogenomic insights into individualised medication discontinuation strategies.

Dissemination of findings

The completed review will be submitted for publication in a peer-reviewed journal.

Data availability

Underlying data

No underlying data are associated with this article.

Extended data

Open Science Framework: The role of pharmacogenomics in the discontinuation of psychotropic medication: a scoping review protocol. https://doi.org/10.17605/OSF.IO/EY7HM³⁹

The project contains the following extended data:

PRISMA-ScR-Checklist_OSF_NS (PRISMA-P checklist)
Search Strategy (Web of Science Search Strategy)

Reporting guidelines

PRISMA-P checklist for ‘The role of pharmacogenomics in the discontinuation of psychotropic medication: a scoping review protocol‘. https://doi.org/10.17605/OSF.IO/EY7HM³⁹

Data are available under the terms of the Creative Commons Zero "No rights reserved" data waiver (CC0 1.0 Public domain dedication).

Faculty Opinions recommended

References

1. Eserian JK, Blanco VP, Mercuri LP, et al.: Current strategies for tapering psychiatric drugs: differing recommendations, impractical doses, and other barriers. Psychiatry Res. 2023; 329: 115537. PubMed Abstract | Publisher Full Text
2. Pergolizzi JV, Varrassi G, Paladini A, et al.: Stopping or decreasing opioid therapy in patients on chronic opioid therapy. Pain Ther. 2019; 8(2): 163–176. PubMed Abstract | Publisher Full Text | Free Full Text
3. Search Glossary: https://www.drugsandalcohol.ie/glossary/info/Psychotropic_drug. Accessed November 6, 2025. Reference Source
4. Maund E, Dewar-Haggart R, Williams S, et al.: Barriers and facilitators to discontinuing antidepressant use: a systematic review and thematic synthesis. J Affect Disord. 2019; 245: 38–62. PubMed Abstract | Publisher Full Text
5. Tondo L, Baldessarini RJ: Discontinuing psychotropic drug treatment. BJPsych Open. 2020; 6(2): e24. PubMed Abstract | Publisher Full Text | Free Full Text
6. Regina AC, Gokarakonda SB, Attia FN: Withdrawal syndromes. StatPearls. September, 2024; Accessed October 30, 2025. Reference Source
7. Cosci F, Chouinard G: Acute and persistent withdrawal syndromes following discontinuation of psychotropic medications. Psychother Psychosom. 2020; 89(5): 283–306. PubMed Abstract | Publisher Full Text
8. Pergolizzi JV, Raffa RB, Rosenblatt MH: Opioid withdrawal symptoms, a consequence of chronic opioid use and opioid use disorder: current understanding and approaches to management. J Clin Pharm Ther. 2020; 45(5): 892–903. PubMed Abstract | Publisher Full Text
9. Zhang MM, Tan X, Zheng YB, et al.: Incidence and risk factors of antidepressant withdrawal symptoms: a meta-analysis and systematic review. Mol Psychiatry. 2025; 30(5): 1758–1769. PubMed Abstract | Publisher Full Text
10. Rodríguez-Espinosa S, Coloma-Carmona A, Pérez-Carbonell A, et al.: Clinical and psychological factors associated with interdose opioid withdrawal in chronic pain population. J Subst Abuse Treat. 2021; 129: 108386. PubMed Abstract | Publisher Full Text
11. Rodríguez-Espinosa S, Coloma-Carmona A, Pérez-Carbonell A, et al.: Tolerance, interdose withdrawal symptoms, and craving predict prescription opioid-use disorder severity in chronic pain patients: a three-wave prospective study. Psychiatry Res. 2024; 342: 116241. PubMed Abstract | Publisher Full Text
12. Bruneau A, Frimerman L, Verner M, et al.: Day-to-day opioid withdrawal symptoms, psychological distress, and opioid craving in patients with chronic pain prescribed opioid therapy. Drug Alcohol Depend. 2021; 225: 108787. PubMed Abstract | Publisher Full Text
13. Murata Y, Kobayashi D, Imuta N, et al.: Effects of the serotonin 1A, 2A, 2C, 3A, and 3B and serotonin transporter gene polymorphisms on the occurrence of paroxetine discontinuation syndrome. J Clin Psychopharmacol. 2010; 30(1): 11–17. PubMed Abstract | Publisher Full Text
14. Chen CH, Wang SC, Tsou HH, et al.: Genetic polymorphisms in CYP3A4 are associated with withdrawal symptoms and adverse reactions in methadone maintenance patients. Pharmacogenomics. 2011; 12(10): 1397–1406. PubMed Abstract | Publisher Full Text
15. Fava GA, Benasi G, Lucente M, et al.: Withdrawal symptoms after serotonin-noradrenaline reuptake inhibitor discontinuation: systematic review. Psychother Psychosom. 2018; 87(4): 195–203. PubMed Abstract | Publisher Full Text
16. Fava GA, Gatti A, Belaise C, et al.: Withdrawal symptoms after selective serotonin reuptake inhibitor discontinuation: a systematic review. Psychother Psychosom. 2015; 84(2): 72–81. PubMed Abstract | Publisher Full Text
17. Simpson KA, Bolshakova M, Kirkpatrick MG, et al.: Characterizing opioid withdrawal experiences and consequences among a community sample of people who use opioids. Subst Use Misuse. 2024; 59(6): 886–894. PubMed Abstract | Publisher Full Text | Free Full Text
18. Henssler J, Heinz A, Brandt L, et al.: Antidepressant withdrawal and rebound phenomena. Dtsch Arztebl Int. 2019; 116(20): 355–361. PubMed Abstract | Publisher Full Text | Free Full Text
19. Henssler J, Schmidt Y, Schmidt U, et al.: Incidence of antidepressant discontinuation symptoms: a systematic review and meta-analysis. Lancet Psychiatry. 2024; 11(7): 526–535. PubMed Abstract | Publisher Full Text
20. Harvey BH, Slabbert FN: New insights on the antidepressant discontinuation syndrome. Hum Psychopharmacol. 2014; 29(6): 503–516. PubMed Abstract | Publisher Full Text
21. Quality statement 4: Stopping antidepressants | Depression in adults | Quality standards | NICE. Reference Source
22. Stopping antidepressants. Accessed October 30, 2025. Reference Source
23. Jeffares I, Friars D, Plapp H, et al.: A scoping review of methods, guidelines, and protocols used for dose reduction or discontinuation of antipsychotic medication in people affected by psychotic disorders. Schizophr Bull. 2025; sbaf181. PubMed Abstract | Publisher Full Text
24. Brandt J, Bressi J, Lê ML, et al.: Prescribing and deprescribing guidance for benzodiazepine and benzodiazepine receptor agonist use in adults with depression, anxiety, and insomnia: an international scoping review. EClinicalMedicine. 2024; 70: 102507. PubMed Abstract | Publisher Full Text | Free Full Text
25. Gupta S, Miller R, Cahill JD: Deprescribing mood stabilizers. Deprescribing in Psychiatry. 2019; 185–198. Publisher Full Text
26. Langford AV, Lin CCW, Bero L, et al.: Clinical practice guideline for deprescribing opioid analgesics: summary of recommendations. Med J Aust. 2023; 219(2): 80–89. PubMed Abstract | Publisher Full Text
27. Vinkers CH, Kupka RW, Penninx BW, et al.: Discontinuation of psychotropic medication: a synthesis of evidence across medication classes. Mol Psychiatry. 2024; 29(8): 2575–2586. PubMed Abstract | Publisher Full Text | Free Full Text
28. Haidar CE, Crews KR, Hoffman JM, et al.: Advancing pharmacogenomics from single-gene to preemptive testing. Annu Rev Genomics Hum Genet. 2022; 23: 449–473. PubMed Abstract | Publisher Full Text | Free Full Text
29. Relling MV, Evans WE: Pharmacogenomics in the clinic. Nature. 2015; 526(7573): 343–50. PubMed Abstract | Publisher Full Text | Free Full Text
30. Keeling NJ, Rosenthal MM, West-Strum D, et al.: Preemptive pharmacogenetic testing: exploring the knowledge and perspectives of US payers. Genet Med. 2019; 21(5): 1224–1232. PubMed Abstract | Publisher Full Text | Free Full Text
31. Stevenson JM, Smith DM, Tuteja S, et al.: Navigating pharmacogenomic testing in practice: who to test and when to test. Clin Pharmacol Ther. 2025; 118(3): 561–566. PubMed Abstract | Publisher Full Text | Free Full Text
32. Weitzel KW, Cavallari LH, Lesko LJ: Preemptive panel-based pharmacogenetic testing: the time is now. Pharm Res. 2017; 34(8): 1551–1555. PubMed Abstract | Publisher Full Text | Free Full Text
33. Chen CH, Wang SC, Tsou HH, et al.: Genetic polymorphisms in CYP3A4 are associated with withdrawal symptoms and adverse reactions in methadone maintenance patients. Pharmacogenomics. 2011; 12(10): 1397–1406. PubMed Abstract | Publisher Full Text
34. Peters MD, Godfrey C, McInerney P, et al.: Scoping reviews. JBI Manual for Evidence Synthesis. 2024. Publisher Full Text
35. Peters MDJ, Godfrey C, McInerney P, et al.: Best practice guidance and reporting items for the development of scoping review protocols. JBI Evid Synth. 2022; 20(4): 953–968. PubMed Abstract | Publisher Full Text
36. Peters MDJ, Marnie C, Tricco AC, et al.: Updated methodological guidance for the conduct of scoping reviews. JBI Evid Implement. 2021; 19(1): 3–10. PubMed Abstract | Publisher Full Text
37. Covidence systematic review software, veritas health innovation, Melbourne, Australia. Reference Source
38. Page MJ, McKenzie JE, Bossuyt PM, et al.: The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021; 372: n71. PubMed Abstract | Publisher Full Text | Free Full Text
39. Stollárová N, Cadogan C: The role of pharmacogenomics in the discontinuation of psychotropic medication: a scoping review protocol. Open Science Framework. Published December 13, 2025. http://www.doi.org/10.17605/OSF.IO/BYSHX

Comments on this article Comments (0)

Version 1

VERSION 1 PUBLISHED 05 Jan 2026

Author details Author details

¹ School of Pharmacy and Pharmaceutical Sciences, Trinity College Dublin, Dublin, Ireland
² Department of Pharmacology and Toxicology, Faculty of Pharmacy, Comenius University Bratislava, Bratislava, Slovakia
³ The Library of Trinity College, Trinity College Dublin, Dublin, Ireland
⁴ Pharmacy Department, Saint John of God University Hospital, Dublin, Stillorgan, Ireland
⁵ Department of Psychiatry, School of Medicine, University College Dublin, Dublin, Ireland

Natalia Stollarova
Roles: Conceptualization, Funding Acquisition, Investigation, Methodology, Project Administration, Writing – Original Draft Preparation

Cristín Ryan
Roles: Writing – Review & Editing

Greg Sheaf
Roles: Methodology, Writing – Review & Editing

Dolores Keating
Roles: Writing – Review & Editing

Brian O’Donoghue
Roles: Writing – Review & Editing

Cathal Cadogan
Roles: Conceptualization, Funding Acquisition, Investigation, Methodology, Project Administration, Writing – Original Draft Preparation

Competing interests

No competing interests were disclosed.

Grant information

Health Research Board Ireland [ILP-HSR-2022-006]. This work was also supported by the Erasmus+ Programme of the European Union.

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Article Versions (1)

version 1

Published: 05 Jan 2026, 9:4

https://doi.org/10.12688/hrbopenres.14314.1

Copyright

© 2026 Stollarova N et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Download

Export To

metrics

VIEWS

24

downloads

3

Citations

0

SEE MORE DETAILS

CITE

how to cite this article

Stollarova N, Ryan C, Sheaf G et al. The role of pharmacogenomics in the discontinuation of psychotropic medication: a scoping review protocol [version 1; peer review: awaiting peer review]. HRB Open Res 2026, 9:4 (https://doi.org/10.12688/hrbopenres.14314.1)

NOTE: If applicable, it is important to ensure the information in square brackets after the title is included in all citations of this article.

track

receive updates on this article

Track an article to receive email alerts on any updates to this article.

Open Peer Review

Comments on this article Comments (0)

Version 1

VERSION 1 PUBLISHED 05 Jan 2026

Open Peer Review

Reviewer Status

AWAITING PEER REVIEW

Comments on this article

All Comments(0)

Add a comment

Sign up for content alerts

[1] 1. Eserian JK, Blanco VP, Mercuri LP, et al.: Current strategies for tapering psychiatric drugs: differing recommendations, impractical doses, and other barriers. Psychiatry Res. 2023; 329: 115537. PubMed Abstract | Publisher Full Text

[2] 2. Pergolizzi JV, Varrassi G, Paladini A, et al.: Stopping or decreasing opioid therapy in patients on chronic opioid therapy. Pain Ther. 2019; 8(2): 163–176. PubMed Abstract | Publisher Full Text | Free Full Text

[3] 3. Search Glossary: https://www.drugsandalcohol.ie/glossary/info/Psychotropic_drug. Accessed November 6, 2025. Reference Source

[4] 4. Maund E, Dewar-Haggart R, Williams S, et al.: Barriers and facilitators to discontinuing antidepressant use: a systematic review and thematic synthesis. J Affect Disord. 2019; 245: 38–62. PubMed Abstract | Publisher Full Text

[5] 5. Tondo L, Baldessarini RJ: Discontinuing psychotropic drug treatment. BJPsych Open. 2020; 6(2): e24. PubMed Abstract | Publisher Full Text | Free Full Text

[6] 6. Regina AC, Gokarakonda SB, Attia FN: Withdrawal syndromes. StatPearls. September, 2024; Accessed October 30, 2025. Reference Source

[7] 7. Cosci F, Chouinard G: Acute and persistent withdrawal syndromes following discontinuation of psychotropic medications. Psychother Psychosom. 2020; 89(5): 283–306. PubMed Abstract | Publisher Full Text

[8] 8. Pergolizzi JV, Raffa RB, Rosenblatt MH: Opioid withdrawal symptoms, a consequence of chronic opioid use and opioid use disorder: current understanding and approaches to management. J Clin Pharm Ther. 2020; 45(5): 892–903. PubMed Abstract | Publisher Full Text

[9] 9. Zhang MM, Tan X, Zheng YB, et al.: Incidence and risk factors of antidepressant withdrawal symptoms: a meta-analysis and systematic review. Mol Psychiatry. 2025; 30(5): 1758–1769. PubMed Abstract | Publisher Full Text

[10] 10. Rodríguez-Espinosa S, Coloma-Carmona A, Pérez-Carbonell A, et al.: Clinical and psychological factors associated with interdose opioid withdrawal in chronic pain population. J Subst Abuse Treat. 2021; 129: 108386. PubMed Abstract | Publisher Full Text

[11] 11. Rodríguez-Espinosa S, Coloma-Carmona A, Pérez-Carbonell A, et al.: Tolerance, interdose withdrawal symptoms, and craving predict prescription opioid-use disorder severity in chronic pain patients: a three-wave prospective study. Psychiatry Res. 2024; 342: 116241. PubMed Abstract | Publisher Full Text

[12] 12. Bruneau A, Frimerman L, Verner M, et al.: Day-to-day opioid withdrawal symptoms, psychological distress, and opioid craving in patients with chronic pain prescribed opioid therapy. Drug Alcohol Depend. 2021; 225: 108787. PubMed Abstract | Publisher Full Text

[13] 13. Murata Y, Kobayashi D, Imuta N, et al.: Effects of the serotonin 1A, 2A, 2C, 3A, and 3B and serotonin transporter gene polymorphisms on the occurrence of paroxetine discontinuation syndrome. J Clin Psychopharmacol. 2010; 30(1): 11–17. PubMed Abstract | Publisher Full Text

[14] 14. Chen CH, Wang SC, Tsou HH, et al.: Genetic polymorphisms in CYP3A4 are associated with withdrawal symptoms and adverse reactions in methadone maintenance patients. Pharmacogenomics. 2011; 12(10): 1397–1406. PubMed Abstract | Publisher Full Text

[15] 15. Fava GA, Benasi G, Lucente M, et al.: Withdrawal symptoms after serotonin-noradrenaline reuptake inhibitor discontinuation: systematic review. Psychother Psychosom. 2018; 87(4): 195–203. PubMed Abstract | Publisher Full Text

[16] 16. Fava GA, Gatti A, Belaise C, et al.: Withdrawal symptoms after selective serotonin reuptake inhibitor discontinuation: a systematic review. Psychother Psychosom. 2015; 84(2): 72–81. PubMed Abstract | Publisher Full Text

[17] 17. Simpson KA, Bolshakova M, Kirkpatrick MG, et al.: Characterizing opioid withdrawal experiences and consequences among a community sample of people who use opioids. Subst Use Misuse. 2024; 59(6): 886–894. PubMed Abstract | Publisher Full Text | Free Full Text

[18] 18. Henssler J, Heinz A, Brandt L, et al.: Antidepressant withdrawal and rebound phenomena. Dtsch Arztebl Int. 2019; 116(20): 355–361. PubMed Abstract | Publisher Full Text | Free Full Text

[19] 19. Henssler J, Schmidt Y, Schmidt U, et al.: Incidence of antidepressant discontinuation symptoms: a systematic review and meta-analysis. Lancet Psychiatry. 2024; 11(7): 526–535. PubMed Abstract | Publisher Full Text

[20] 20. Harvey BH, Slabbert FN: New insights on the antidepressant discontinuation syndrome. Hum Psychopharmacol. 2014; 29(6): 503–516. PubMed Abstract | Publisher Full Text

[21] 21. Quality statement 4: Stopping antidepressants | Depression in adults | Quality standards | NICE. Reference Source

[22] 22. Stopping antidepressants. Accessed October 30, 2025. Reference Source

[23] 23. Jeffares I, Friars D, Plapp H, et al.: A scoping review of methods, guidelines, and protocols used for dose reduction or discontinuation of antipsychotic medication in people affected by psychotic disorders. Schizophr Bull. 2025; sbaf181. PubMed Abstract | Publisher Full Text

[24] 24. Brandt J, Bressi J, Lê ML, et al.: Prescribing and deprescribing guidance for benzodiazepine and benzodiazepine receptor agonist use in adults with depression, anxiety, and insomnia: an international scoping review. EClinicalMedicine. 2024; 70: 102507. PubMed Abstract | Publisher Full Text | Free Full Text

[25] 25. Gupta S, Miller R, Cahill JD: Deprescribing mood stabilizers. Deprescribing in Psychiatry. 2019; 185–198. Publisher Full Text

[26] 26. Langford AV, Lin CCW, Bero L, et al.: Clinical practice guideline for deprescribing opioid analgesics: summary of recommendations. Med J Aust. 2023; 219(2): 80–89. PubMed Abstract | Publisher Full Text

[27] 27. Vinkers CH, Kupka RW, Penninx BW, et al.: Discontinuation of psychotropic medication: a synthesis of evidence across medication classes. Mol Psychiatry. 2024; 29(8): 2575–2586. PubMed Abstract | Publisher Full Text | Free Full Text

[28] 28. Haidar CE, Crews KR, Hoffman JM, et al.: Advancing pharmacogenomics from single-gene to preemptive testing. Annu Rev Genomics Hum Genet. 2022; 23: 449–473. PubMed Abstract | Publisher Full Text | Free Full Text

[29] 29. Relling MV, Evans WE: Pharmacogenomics in the clinic. Nature. 2015; 526(7573): 343–50. PubMed Abstract | Publisher Full Text | Free Full Text

[30] 30. Keeling NJ, Rosenthal MM, West-Strum D, et al.: Preemptive pharmacogenetic testing: exploring the knowledge and perspectives of US payers. Genet Med. 2019; 21(5): 1224–1232. PubMed Abstract | Publisher Full Text | Free Full Text

[31] 31. Stevenson JM, Smith DM, Tuteja S, et al.: Navigating pharmacogenomic testing in practice: who to test and when to test. Clin Pharmacol Ther. 2025; 118(3): 561–566. PubMed Abstract | Publisher Full Text | Free Full Text

[32] 32. Weitzel KW, Cavallari LH, Lesko LJ: Preemptive panel-based pharmacogenetic testing: the time is now. Pharm Res. 2017; 34(8): 1551–1555. PubMed Abstract | Publisher Full Text | Free Full Text

[33] 33. Chen CH, Wang SC, Tsou HH, et al.: Genetic polymorphisms in CYP3A4 are associated with withdrawal symptoms and adverse reactions in methadone maintenance patients. Pharmacogenomics. 2011; 12(10): 1397–1406. PubMed Abstract | Publisher Full Text

[34] 34. Peters MD, Godfrey C, McInerney P, et al.: Scoping reviews. JBI Manual for Evidence Synthesis. 2024. Publisher Full Text

[35] 35. Peters MDJ, Godfrey C, McInerney P, et al.: Best practice guidance and reporting items for the development of scoping review protocols. JBI Evid Synth. 2022; 20(4): 953–968. PubMed Abstract | Publisher Full Text

[36] 36. Peters MDJ, Marnie C, Tricco AC, et al.: Updated methodological guidance for the conduct of scoping reviews. JBI Evid Implement. 2021; 19(1): 3–10. PubMed Abstract | Publisher Full Text

[37] 37. Covidence systematic review software, veritas health innovation, Melbourne, Australia. Reference Source

[38] 38. Page MJ, McKenzie JE, Bossuyt PM, et al.: The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021; 372: n71. PubMed Abstract | Publisher Full Text | Free Full Text

[39] 39. Stollárová N, Cadogan C: The role of pharmacogenomics in the discontinuation of psychotropic medication: a scoping review protocol. Open Science Framework. Published December 13, 2025. http://www.doi.org/10.17605/OSF.IO/BYSHX

The role of pharmacogenomics in the discontinuation of psychotropic medication: a scoping review protocol

Abstract

Introduction

Objective

Methods

Conclusion

Keywords

Introduction

Methods

Scoping review question

What is the available evidence regarding the role of pharmacogenomics (concept) on patients treated with psychotropic medications (population) in the process of the medication discontinuation (context)?

Defining and aligning the objectives and research question

Eligibility criteria

Table 1. Eligibility criteria for literature inclusion in the scoping review.

Information sources

Table 2. Relevant search terms following the Population Concept Context (PCC) framework with keywords for Web of Science.

Search strategy

Table 3. Search strategy for Web of Science.

Data charting

Critical appraisal

Data analysis and synthesis

Discussion

Dissemination of findings

Data availability

Underlying data

Extended data

Reporting guidelines

References

Comments on this article Comments (0)

Open Peer Review

Comments on this article Comments (0)

Open Peer Review

Reviewer Status

Comments on this article

Are you a HRB-funded researcher?

Thank you!

The role of pharmacogenomics in the discontinuation of psychotropic medication: a scoping review protocol

Abstract

Introduction

Objective

Methods

Conclusion

Keywords

Introduction

Methods

Scoping review question

What is the available evidence regarding the role of pharmacogenomics (concept) on patients treated with psychotropic medications (population) in the process of the medication discontinuation (context)?

Defining and aligning the objectives and research question

Eligibility criteria

Table 1. Eligibility criteria for literature inclusion in the scoping review.

Information sources

Table 2. Relevant search terms following the Population Concept Context (PCC) framework with keywords for Web of Science.

Search strategy

Table 3. Search strategy for Web of Science.

Data charting

Critical appraisal

Data analysis and synthesis

Discussion

Dissemination of findings

Data availability

Underlying data

Extended data

Reporting guidelines

References

Comments on this article Comments (0)

Open Peer Review

Comments on this article Comments (0)

Open Peer Review

Reviewer Status

Comments on this article

Competing Interests Policy

Stay Updated

Are you a HRB-funded researcher?

Thank you!